BioNexus Gene Lab and Fidelion Diagnostics Form Strategic Alliance, with “DeepSeek Moment” in Precision Oncology
DENVER, Colo., Jul 30, 2025 (247marketnews.com)- BioNexus Gene Lab (NASDAQ:BGLC) and Singapore-based Fidelion Diagnostics announced a strategic cross-equity partnership, described by both parties as a “DeepSeek-class leap” in liquid biopsy cancer monitoring and AI-driven biotech innovation.
BGLC will acquire a strategic stake in Fidelion and exclusive commercial rights to its VitaGuard minimal residual disease (MRD) platform across Southeast Asia (ASEAN). In return, Fidelion will receive an equity investment and license fee from BGLC. The agreement is subject to final documentation.
“This alliance is nothing short of a paradigm shift- the moment precision oncology gets its own ‘DeepSeek-class’ technology upgrade,” said Sam Tan, CEO of BGLC. “We will deliver next-generation cancer care to 680 million people across Southeast Asia.”
VitaGuard enables non-invasive, blood-based cancer monitoring, known as liquid biopsy, without needing tissue from the original tumor (“tumor-naïve”). This allows earlier, more cost-effective detection, with test costs under $300 vs. ~$3,000 for current U.S.-based options.
Developed by China’s Tongshu Gene Biotechnology, VitaGuard is already commercialized in China and backed by positive clinical studies. Fidelion will act as its global licensing arm. With cancer cases in Southeast Asia projected to exceed 2.4 million annually by 2030, the test presents a multi-billion-dollar market opportunity.
Dr. Yan Linghua, CEO of Tongshu Gene and Fidelion’s Executive Director, added, “Our team spent years perfecting VitaGuard’s one-tube, high-fidelity chemistry. Partnering with BGLC creates the fastest path to scale. Together, we aim to shatter the cost-accuracy trade-off.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com